HC Wainwright Has Optimistic Outlook of CORT Q3 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Investment analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Thursday, May 28th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings of $0.34 per share for the quarter, up from their prior forecast of $0.33. HC Wainwright currently has a “Buy” rating and a $95.00 price target on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.52 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $0.80 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). The company had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.17 earnings per share.

CORT has been the subject of several other research reports. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Piper Sandler raised their target price on Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Wolfe Research raised Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a research report on Thursday, March 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $88.83.

Corcept Therapeutics Stock Up 2.6%

Shares of Corcept Therapeutics stock opened at $68.38 on Friday. The stock has a market cap of $7.34 billion, a PE ratio of 195.38 and a beta of 0.36. The business has a fifty day simple moving average of $47.30 and a 200-day simple moving average of $52.18. Corcept Therapeutics has a 12 month low of $28.66 and a 12 month high of $91.00.

Insiders Place Their Bets

In other news, CEO Joseph K. Belanoff sold 26,198 shares of the firm’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the completion of the sale, the chief executive officer directly owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. This trade represents a 0.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director G Leonard Baker, Jr. purchased 100,000 shares of Corcept Therapeutics stock in a transaction dated Tuesday, March 17th. The shares were purchased at an average price of $33.14 per share, with a total value of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares in the company, valued at $37,999,351.34. The trade was a 9.55% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold a total of 86,198 shares of company stock valued at $3,887,769 in the last three months. Insiders own 20.70% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several large investors have recently made changes to their positions in the company. Parallel Advisors LLC grew its stake in shares of Corcept Therapeutics by 2.5% in the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after buying an additional 96,763 shares in the last quarter. State Street Corp grew its stake in shares of Corcept Therapeutics by 0.5% in the 4th quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after buying an additional 15,656 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Corcept Therapeutics by 38.0% in the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares in the last quarter. First Trust Advisors LP grew its stake in shares of Corcept Therapeutics by 213.5% in the 1st quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock valued at $87,609,000 after buying an additional 1,480,059 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock valued at $55,404,000 after buying an additional 405,081 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Canaccord Genuity raised its price target on Corcept Therapeutics to $135 from $110 and maintained a buy rating, signaling stronger upside expectations for Corcept Therapeutics (NASDAQ:CORT) Given New $135.00 Price Target at Canaccord Genuity Group
• Positive Sentiment: HC Wainwright also lifted its valuation, increasing its price target to $95 and raising EPS forecasts for Q3, Q4, and full-year 2026, reflecting higher profit expectations for Corcept. HC Wainwright analyst note
• Positive Sentiment: Corcept said it plans to resubmit the NDA for relacorilant in Cushing’s syndrome, which investors appear to view as a key step toward a potential future approval and revenue opportunity. Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
• Neutral Sentiment: Stockholders approved an expanded incentive plan and board-related matters at the annual meeting, a routine governance update with limited direct near-term impact on the stock. Corcept stockholders approve expanded incentive plan and board
• Negative Sentiment: There were also references to Corcept’s prior earnings miss, which still hangs over sentiment, though the newer analyst revisions suggest investors are focusing more on future growth than the last quarter’s results.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.